DE60129573D1 - Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat - Google Patents

Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Info

Publication number
DE60129573D1
DE60129573D1 DE60129573T DE60129573T DE60129573D1 DE 60129573 D1 DE60129573 D1 DE 60129573D1 DE 60129573 T DE60129573 T DE 60129573T DE 60129573 T DE60129573 T DE 60129573T DE 60129573 D1 DE60129573 D1 DE 60129573D1
Authority
DE
Germany
Prior art keywords
fenofibrate
spray drying
compositions containing
powdered compositions
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129573T
Other languages
English (en)
Other versions
DE60129573T2 (de
Inventor
Gary Pace
Awadhesh K Mishra
Robert A Snow
Indu Parikh
H Pol-Henri Dr Guivarc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Publication of DE60129573D1 publication Critical patent/DE60129573D1/de
Application granted granted Critical
Publication of DE60129573T2 publication Critical patent/DE60129573T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
DE60129573T 2000-09-20 2001-04-20 Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat Expired - Lifetime DE60129573T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23418600P 2000-09-20 2000-09-20
US234186P 2000-09-20
US24176100P 2000-10-20 2000-10-20
US241761P 2000-10-20
US27015701P 2001-02-22 2001-02-22
US270157P 2001-02-22
PCT/US2001/012746 WO2002024169A1 (en) 2000-09-20 2001-04-20 Spray drying process and compositions of fenofibrate

Publications (2)

Publication Number Publication Date
DE60129573D1 true DE60129573D1 (de) 2007-09-06
DE60129573T2 DE60129573T2 (de) 2008-04-17

Family

ID=27398528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129573T Expired - Lifetime DE60129573T2 (de) 2000-09-20 2001-04-20 Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Country Status (9)

Country Link
US (1) US6696084B2 (de)
EP (1) EP1322289B1 (de)
AT (1) ATE367802T1 (de)
AU (2) AU2001262945B2 (de)
CA (1) CA2423335C (de)
DE (1) DE60129573T2 (de)
NZ (1) NZ525306A (de)
TW (1) TWI293877B (de)
WO (1) WO2002024169A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
ID29270A (id) * 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
EP1499296B1 (de) * 2002-04-15 2012-04-04 MAP Pharmaceuticals Inc Formulierung aus feinen teilchen mit verflüssigten oder dichten gasen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
NO346970B1 (no) * 2002-05-24 2023-03-20 Alkermes Pharma Ireland Ltd Nanopartikulære fiberformuleringer
EP1531799A1 (de) * 2002-06-10 2005-05-25 Elan Pharma International Limited Pharmazeutische nanopartikel-formulierungen mit hmg-coa-reduktase-inhibitoren ("statine"), neue kombinationen davon sowie herstellung dieser pharmazeutischen zusammensetzungen
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
PT1515890E (pt) * 2002-06-27 2012-10-18 Novartis Ag Dispositivo e método para controlar o escoamento de um pó
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004096113A2 (en) 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
JP2007508249A (ja) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ フィブラートとスタチンを含む固体剤型
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Ｈｄｌを高める併用療法用複合物
EP1730516A1 (de) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
EP1729734B1 (de) * 2004-03-30 2008-02-27 Smithkline Beecham Corporation Sprühgetrocknete pharmazeutische zusammensetzungen
US7101585B2 (en) * 2004-04-15 2006-09-05 Solae, Llc Ultra high pressure homogenization process for making a stable protein based acid beverage
US7306562B1 (en) * 2004-04-23 2007-12-11 Medical Software, Llc Medical risk assessment method and program product
GB0411502D0 (en) * 2004-05-22 2004-06-23 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US7495052B2 (en) * 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
WO2006037345A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibrate and simvastatin
CA2582403A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
EP1853249A2 (de) * 2005-02-10 2007-11-14 LifeCycle Pharma A/S Stabile pharmazeutische zusammensetzung aus einer fixdosen-kombination von fenofibrat und einem hmg-coa-reductase-hemmer
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
US20060223882A1 (en) * 2005-03-23 2006-10-05 Venkataraman Sundaram Amorphous simvastatin
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
WO2006107411A2 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and surfacant mixture
EA200701750A1 (ru) * 2005-03-30 2008-02-28 Тева Фармасьютикал Индастриес Лтд. Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер
CA2604970A1 (en) * 2005-04-13 2006-08-17 Lifecycle Pharma A/S A tablet comprising a fibrate
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
EP1808162A1 (de) * 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Pharmazeutische Formulierung von Atorvastatin
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1803441B1 (de) * 2005-12-28 2009-04-29 Teva Pharmaceutical Industries Ltd Pharmazeutische Formulierungen mit Fenofibrat mit verbesserter Bioverfügbarkeit
JP2009522258A (ja) * 2005-12-28 2009-06-11 テバ ファーマシューティカル インダストリーズ リミティド 増大したバイオアベイラビリティを有するフェノフィブラートの医薬製剤
EP1905424A3 (de) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die stabilisierte Statin-Partikel enthält
US20090140212A1 (en) * 2006-02-24 2009-06-04 Friedman Joel M Electron Transfer Through Glassy Matrices
US9222728B2 (en) 2006-04-24 2015-12-29 Medinstill Development Llc Penetrable and resealable lyophilization device
EP1870649A1 (de) * 2006-06-20 2007-12-26 Octapharma AG Gefriertocknung zum Erzielen einer bestimmte Restfeuchte durch beschränkte Desorptionsenergiepegeln.
US20080050450A1 (en) * 2006-06-26 2008-02-28 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US7877895B2 (en) 2006-06-26 2011-02-01 Tokyo Electron Limited Substrate processing apparatus
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
AU2007275634B2 (en) * 2006-07-21 2011-01-20 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
US20080132560A1 (en) * 2006-11-21 2008-06-05 San-Laung Chow Solid dispersion composition
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US7908765B2 (en) * 2006-12-22 2011-03-22 Collette Nv Continuous granulating and drying apparatus
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
EP2240162A4 (de) * 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
EP2231169B1 (de) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US20090182053A1 (en) * 2007-12-19 2009-07-16 Tong Sun Fenofibric acid amorphous dispersion; method of making; and method of use thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EP3130396B1 (de) 2009-03-27 2021-03-17 Bend Research, Inc. Sprühtrocknungsverfahren
KR100980749B1 (ko) 2009-12-17 2010-09-07 삼일제약주식회사 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
PT2611529T (pt) 2010-09-03 2019-05-09 Bend Res Inc Método de secagem por pulverização
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
EP2618924A1 (de) 2010-09-24 2013-07-31 Bend Research, Inc. Hochtemperatur-sprühtrocknungsverfahren und verfahren
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
MX2013006332A (es) * 2013-06-05 2014-12-19 Alparis Sa De Cv Composiciones farmaceuticas orales para uso en dislipidemias.
EP2878311A1 (de) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Verbesserung der Löslichkeit für hydrophobe Wirkstoffe
EP3154528B1 (de) 2014-06-11 2023-04-05 SpecGx LLC Sprühgetrocknete zusammensetzungen mit verschiedenen auflösungsprofilen und verfahren zu deren herstellung
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
WO2016067132A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
ES2929526T3 (es) 2015-06-22 2022-11-29 Arena Pharm Inc Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US10627161B2 (en) * 2018-01-24 2020-04-21 King Abdulaziz City for Science and Technology (KACST) Laboratory equipment and method of using the same for drying a starting material to produce nano material
WO2022183281A1 (en) * 2021-03-03 2022-09-09 Mcmaster Christopher R Compounds and treatments for muscular dystrophy
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
US11841189B1 (en) * 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329446A1 (de) 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
DE69728206T2 (de) 1996-05-14 2005-03-10 Dsm Ip Assets B.V. Herstellungsverfahren für Carotenoid-Zusammensetzungen
DE69734988T2 (de) * 1996-08-22 2006-09-21 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen stoffen und verfahren zu deren herstellung
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten

Also Published As

Publication number Publication date
AU2001262945B2 (en) 2006-02-02
ATE367802T1 (de) 2007-08-15
CA2423335A1 (en) 2002-03-28
TWI293877B (en) 2008-03-01
NZ525306A (en) 2004-11-26
EP1322289B1 (de) 2007-07-25
AU6294501A (en) 2002-04-02
EP1322289A1 (de) 2003-07-02
DE60129573T2 (de) 2008-04-17
CA2423335C (en) 2011-03-01
US20020056206A1 (en) 2002-05-16
US6696084B2 (en) 2004-02-24
WO2002024169A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
DE60129573D1 (de) Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
KR100757155B1 (ko) 저용량의 엔테카비르 제제 및 그의 용도
EA029890B1 (ru) Фармацевтическая композиция и фармацевтическая композиция в пероральной дозированной лекарственной форме на основе ингибитора dpp iv
FI101040B (fi) Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi
CA2874779C (en) Pharmaceutical composition of entecavir and process of manufacturing
MXPA04007427A (es) Formulaciones de azitromicina granuladas por via seca.
HUP0202781A2 (hu) Béta-karbolin szemcsés formája, ezt tartalmazó gyógyszerkészítmények, előállításaik és alkalmazásuk
NO20011211D0 (no) Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme
MY127350A (en) Flash-melt oral dose formulations
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
CA2435714A1 (en) Fenofibrate tablets
RU2199312C1 (ru) Способ получения лекарственных средств из растительных экстрактов в твердой форме
JPH0225428A (ja) 苦味の軽減方法および苦味軽減組成物
NL8202773A (nl) Apap-antizuur-samenstelling.
RU2287338C2 (ru) Способ получения таблеток из сухого экстракта зверобоя
Akiladevi et al. A Study on the Effect of disintegrants and Processing Methods on the Physicochemical and In Vitro Release Characteristics of Immediate Release Tablets of Bosentan Monohydrate
RU2166942C1 (ru) Фармацевтический состав, обладающий противотуберкулезным действием, и способ его получения
RU2188017C1 (ru) Способ получения таблеток комбинированного препарата триметоприма с сульфаметоксазолом
EP3900708A1 (de) Zaltoprofen enthaltendes arzneimittel mit verzögerter freisetzung
RU2163121C1 (ru) Средство от простуды
AU2006235960B2 (en) Low dose entecavir formulation and use
RU2195286C1 (ru) Твердая лекарственная форма, содержащая глицирам
RU2190403C1 (ru) Фармацевтическая композиция, обладающая антибактериальным действием, и способ ее получения
RU2207128C2 (ru) Диуретическое и гипотензивное средство
NZ533283A (en) High-dosage nelfinavir tablet comprising nelfinavir mesylate in an amount of up to 730 mg

Legal Events

Date Code Title Description
8364 No opposition during term of opposition